MONALEESA-3: Quality of Life Analysis
Ribociclib + Fulvestrant in Advanced Breast Cancer (HR+/HER2-)
Executive Summary: While adding a CDK4/6 inhibitor typically introduces toxicity risks, this study demonstrates that Ribociclib maintains Quality of Life (QOL) comparable to placebo while significantly delaying the time to definitive deterioration (TTD) across key functional and symptom scales.
0.81
HR for Global Health Deterioration
35.9 mo
Median TTD (Ribociclib)
0.77
HR for Pain Severity Deterioration
Study Design & Population
Baseline Quality of Life Scores
Comparison of EORTC QLQ-C30 Global Health and Pain scores at baseline shows balanced cohorts.
Risk of Deterioration (Hazard Ratios)
Hazard Ratios < 1.0 indicate Ribociclib delays deterioration. Error bars represent 95% CI.
Time to Definitive Deterioration (Months)
Comparison of median/mean months until 10% deterioration occurs. Longer bars indicate preserved quality of life.
Magnitude of Benefit (Months Gained)
Absolute difference in months to deterioration (Ribociclib - Placebo).
Key Performance Indicators
Appendix: Data & Provenance
| Metric | Group | Value | Source |
|---|
Source: | DOI: